Search bioRxiv⌕ Search

Biology subjects

Phanthanawiboon, S.

Publications and source records attributed to Phanthanawiboon, S..

2 recordsLinked to original sources

Machine learning-based framework for predicting human infection potential of coronavirus associated with tri-amino acid motifs, KIQ and LEP in spike protein

Assessing the human infection potential of emerging coronaviruses remains a critical challenge for global health preparedness. In this study, we developed a machine learning-based framework to predict the human infection potential of coronaviruses and to identify associated sequence motifs using spike (S) protein sequences. A total of 3,904 complete S protein sequences were collected, annotated as human or non-human infection and encoded using trimer-based k-mer features. Model benchmarking was conducted across 27 machine learning algorithms, followed by hyperparameter optimization of the selected model. Robustness and generalizability were evaluated using k-fold cross-validation and independent external validation. Feature interpretability was further assessed using SHAP analysis to identify sequence determinants associated with infection potential. The Random Forest classifier achieved the best performance, with accuracy, sensitivity, and specificity of 97.8%, 99%, and 97.4%, respectively, and demonstrated stable predictive performance across validation datasets. Notably, the KIQ and LEP motifs were strongly associated with human infection coronaviruses and mapped to the HR1 and N-terminal domain regions of the S protein. Overall, this framework provides a practical approach for risk assessment and surveillance of emerging coronaviruses. Author summaryEmerging coronaviruses continue to threaten global public health, but rapidly identifying viruses with the potential to infect humans remains challenging. Traditional experimental approaches are time-consuming and resource-intensive, limiting their use for large-scale surveillance. In this study, we developed a machine learning based workflow to assess the human infection potential of coronaviruses using spike protein sequences. By analyzing sequence patterns across a diverse set of coronaviruses, our framework enables rapid screening of coronaviruses from multiple host species. Unlike previous studies focused on limited coronavirus genera, our approach integrates all four genera and systematically evaluates multiple learning strategies. Importantly, our analysis identifies conserved sequence motifs linked to human infection potential, bridging predictive performance with biological interpretability. Our findings demonstrate computational approaches support early warning systems for identifying high risk coronaviruses, contributing to prioritize viruses for experimental validation, guide surveillance efforts, and strengthen global pandemic preparedness under a One Health perspective.

bioinformatics↗

A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome

Severe fever with thrombocytopenia syndrome (SFTS) caused by Dabie bandavirus (formerly SFTS virus [SFTSV]) is an emerging hemorrhagic infectious disease with a high case-fatality rate. One of the best strategies for preventing SFTS is to develop a vaccine, which is expected to induce both humoral and cellular immunity. We applied a highly attenuated but still immunogenic vaccinia virus strain LC16m8 (m8) as a recombinant vaccine for SFTS. Recombinant m8s expressing SFTSV nucleoprotein (m8-N), envelope glycoprotein precursor (m8-GPC), and both N and GPC (m8-N+GPC) in the infected cells were generated. Both m8-GPC- and m8-N+GPC-infected cells were confirmed to produce SFTSV-like-particles (VLP) in vitro, and the N was incorporated in the VLP produced by the infection of cells with m8-N+GPC. Specific antibodies to SFTSV were induced in mice inoculated with each of the recombinant m8s, and the mice were fully protected from lethal challenge with SFTSV at both 103 TCID50 and 105 TCID50. In mice that had been immunized with vaccinia virus strain Lister in advance of m8-based SFTSV vaccine inoculation, protective immunity against the SFTSV challenge was also conferred. The pathological analysis revealed that mice immunized with m8-GPC or m8-N+GPC did not show any histopathological changes without any viral antigen-positive cells, whereas the control mice showed focal necrosis with inflammatory infiltration with SFTSV antigen-positive cells in tissues after SFTSV challenge. The passive serum transfer experiments revealed that sera collected from mice inoculated with m8-GPC or m8-N+GPC but not with m8-N conferred protective immunity against lethal SFTSV challenge in naive mice. On the other hand, the depletion of CD8-positive cells in vivo did not abrogate the protective immunity conferred by m8-based SFTSV vaccines. Based on these results, the recombinant m8-GPC and m8-N+GPC were considered promising vaccine candidates for SFTS. Author SummarySevere fever with thrombocytopenia syndrome (SFTS) is an emerging viral hemorrhagic fever with a high case-fatality rate (approximately 5% to >40%). Indigenous SFTS has been reported in China, Japan, South Korea, and Vietnam. Thus, the development of an effective vaccine for SFTS is urgently needed. Vaccinia virus (VAC) was previously used as a vaccine for smallpox. Unfortunately, after these strains, the so-called second generation of VAC used during the eradication campaign was associated with severe adverse events, and the third generation of VAC strains such as LC16m8 (m8) and modified vaccinia Ankara (MVA) was established. m8 is confirmed to be highly attenuated while still maintaining immunogenicity. m8 is licensed for use in healthy people in Japan. At the present time, approximately 100,000 people have undergone vaccination with m8 without experiencing any severe postvaccine complications. At present, third-generation VAC strains are attractive for a recombinant vaccine vector, especially for viral hemorrhagic infectious diseases, such as Ebola virus disease, Lassa fever, Crimean-Congo hemorrhagic fever, and SFTS. We investigated the practicality of an m8-based recombinant vaccine for SFTS as well as other promising recombinant VAC-based vaccines for viral hemorrhagic infectious diseases.

microbiology↗